Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.
Loading...
Embargo End Date
ICR Authors
Authors
Gao, M
Callari, M
Beddowes, E
Sammut, S-J
Grzelak, M
Biggs, H
Jones, L
Boumertit, A
Linn, SC
Cortes, J
Oliveira, M
Baird, R
Chin, S-F
Caldas, C
Callari, M
Beddowes, E
Sammut, S-J
Grzelak, M
Biggs, H
Jones, L
Boumertit, A
Linn, SC
Cortes, J
Oliveira, M
Baird, R
Chin, S-F
Caldas, C
Document Type
Journal Article
Date
2019-01-04
Date Accepted
2018-12-17
Abstract
Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical utility in oncology. We describe here a fast, flexible and cost-effective method to profile multiple genes simultaneously in low input cell-free DNA (cfDNA): Next Generation-Targeted Amplicon Sequencing (NG-TAS). We designed a panel of 377 amplicons spanning 20 cancer genes and tested the NG-TAS pipeline using cell-free DNA from two HapMap lymphoblastoid cell lines. NG-TAS consistently detected mutations in cfDNA when mutation allele fraction was > 1%. We applied NG-TAS to a clinical cohort of metastatic breast cancer patients, demonstrating its potential in monitoring the disease. The computational pipeline is available at https://github.com/cclab-brca/NGTAS_pipeline .
Citation
Genome Medicine, 2019, 11 (1), pp. 1 -
Source Title
Genome Medicine
Publisher
BMC
ISSN
1756-994X
eISSN
1756-994X
Collections
Research Team
Cancer Dynamics